Loading...
Challenges and Strategies in Drug Delivery Systems for Treatment of Pulmonary Infections.
Ho, Duy-Khiet Nichols, Brittany L B Edgar, Kevin J Murgia, Xabier Loretz, Brigitta Lehr, Claus-Michael
Ho, Duy-Khiet
Nichols, Brittany L B
Edgar, Kevin J
Murgia, Xabier
Loretz, Brigitta
Lehr, Claus-Michael
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2019-09-04
Submitted date
Files
Loading...
original manuscript
Adobe PDF, 893.69 KB
Other Titles
Abstract
Inhalation therapy has been reported as the most effective treatment for respiratory bacterial infections due to the increasing relevance of drug bioavailability. Drug delivery systems (DDS) have the capacity to overcome pulmonary biological barriers limiting the bioavailability of inhaled anti-infectives. This is important to eradicate bacterial infections and to prevent the development of bacterial resistance. Despite substantial efforts in the field, the current state-of-the-art often fails to achieve those goals, and we still observe increasing bacterial resistance. We give a brief insight on benefits and challenges in pulmonary delivery of anti-infectives. In the context of drug delivery development for pulmonary infections, particularly focusing on Pseudomonas aeruginosa (PA) infections, this mini review will critically discuss the main requirements, as well as the recent strategies of drug delivery system synthesis and preparation. Finally, interaction of DDS with crucial pulmonary biological barriers will be of great importance for the success of future applications of the developed DDS.
Citation
Eur J Pharm Biopharm. 2019 Sep 4. pii: S0939-6411(19)30620-4. doi: 10.1016/j.ejpb.2019.09.002.
Publisher
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1873-3441
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution-NonCommercial-ShareAlike 4.0 International